Skip to main content
OpenTrials
Completed

NCT Number: NCT01318278

Study of Dopamine Versus Vasopressin for Treatment of Low Blood Pressure in Low Birth Weight Infants

Low blood pressure or hypotension is a very important problem that is often seen in premature babies, especially those with low birth weight. Severe hypotension leads to significant problems including brain bleeds, developmental delays, kidney and liver problems, and other issues that can affect babies for the rest of their lives. An important aspect in the management of infants with hypotension is the decision of when to treat and with what agent. Research is being conducted to try to find the best medication to use in these situations. Dopamine is often used first, but it does not always prove to be effective, and it has several concerning side effects. This study will look at vasopressin, which has fewer side effects, as a first-line medication for low blood pressure in extremely low birth weight infants.

Hypotheses and Specific Aims: This study will show superiority of vasopressin to dopamine in preterm, extremely low birth weight infants who have hypotension within the first 24 hours of life. We will specifically look at its ability to raise blood pressure values, improve clinical symptoms seen, any adverse effects, and clinical outcomes of babies being treated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypotension Cardiovascular Diseases Diabetes Insipidus Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Pituitary Diseases Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

Up to 24 hour

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Texas Children's Hospital

Houston, Texas, 77030, United States

About this study

Hypotension in the low birth weight (LBW) and extremely low birth weight (ELBW) infant is often encountered in the postnatal adaptation phase. Severe, prolonged hypotension contributes to cellular dysfunction and cell death. Systemic hypotension affects close to half of all ELBW infants and a significant portion of LBW infants. The true definition of hypotension remains to be a question. There is a linear association between birth weight, gestational age, and mean blood pressure but blood pressure can vary significantly in the first day of life. The critical period tends to be the first 24-36 hours of life as blood pressure tends to rise significantly in the first 72 hours of life regardless of gestational age. Preterm infants suffering from hypotension have a higher incidence and increased severity of intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), and long-term neurodevelopmental sequelae compared to normotensive preterm infants. Effects on other organ systems can result in renal injury, hepatic injury, and the development of necrotizing enterocolitis among other complications. An important aspect in the management of infants with hypotension is the decision of when to treat and with what agent. Dopamine is commonly used as first-line therapy, but issues with efficacy and its side effect profile have lessened its favorability over the years. Few studies compare dopamine to other agents as a first -line treatment. This study hopes to contribute to the literature information on vasopressin as a potential first-line agent for treatment of neonatal hypotension in low birth weight infants.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Infants less than 24 hours of age
  • Infants with birth weight of <1001 grams and/or gestational age of <29 weeks
  • Not initiated on any continuous pressor therapy prior to enrollment
  • Intravenous line in place
  • Outborn infants meeting eligibility criteria

Exclusion criteria

  • Infants not meeting eligibility criteria
  • Infants with life-threatening congenital defects
  • Infants with congenital hydrops
  • Infants with frank hypovolemia (perinatal history consistent with decreased circulating blood volume plus clinical signs of hypovolemia)
  • Infants with other unresolved causes of hypotension (air leaks, lung overdistention, or metabolic abnormalities).

Treatment and study plan

Dopamine

Drug

dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy

Other names: Dopamine Hydrochloride

Arginine vasopressin

Drug

vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy

Other names: Vasopressin, Antidiuretic Hormone (ADH), Pitressin (US brand name), Pressyn;Pressyn AR (Canadian brand names), Argipressin

Primary outcomes

  1. Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life

    Time frame: 24 hours of life

    Optimal mean blood pressure (OMBP) will be defined as either a 10% increase in mean blood pressure value or a 2-3 mmHg rise in mean blood pressure value AND an improvement in tissue perfusion as demonstrated by a resolution in the specified clinical symptom (designated upon enrollment) within 4-6 hours of having reached OMBP

Secondary outcomes

  1. Heart Rate Change From Baseline

    Time frame: 96 hours or until hypotension completely resolved and medications stopped

    Heart rate change from baseline during study drug administration

  2. Acid-base Status

    Time frame: 96 hours or until hypotension resolved and medication completely stopped

  3. Hyponatremia

    Time frame: 96 hours or until medication completely stopped

  4. Urine Output

    Time frame: 96 hours or until hypotension resolved and medication completely stopped

  5. Evidence of Ischemic Changes

    Time frame: 96 hours or until medication completely stopped

    Physical examinations were done on at least a twice daily basis to evaluate for any ischemic lesions (especially on the limbs) of all subjects. The presence of any lesion considered to be due to ischemia would have been reported in this data.

  6. Necrotizing Enterocolitis

    Time frame: until hospital discharge, up to 12 weeks

  7. Ventilator Days

    Time frame: Until hospital discharge, up to 15 months

  8. Presence of Patent Ductus Arteriosus (PDA)

    Time frame: until hospital discharge, up to 12 weeks

  9. Grade 3 Intraventricular Hemorrhage or Worse on Head Ultrasound

    Time frame: Until hospital discharge, up to 15 months

  10. Retinopathy of Prematurity Stage 3 or Higher

    Time frame: Until hospital discharge, up to 15 months

    All subjects were followed by an ophthalmologist with initial exam at 4-6 weeks of age. The Stages describe the ophthalmoscopic findings at the junction between the vascularized and avascular retina. Each subject is followed until cleared by ophthalmology. For this outcome measure, the most severe stage of disease was used in analysis.

    Stage 1 is a faint demarcation line. Stage 2 is an elevated ridge. Stage 3 is extraretinal fibrovascular proliferation (neovascularization). Stage 4 is sub-total retinal detachment. Stage 5 is total retinal detachment. Stages 1 and 2 do not lead to blindness. However, they can progress to the more severe stages.

  11. Presence of Bronchopulmonary Dysplasia (BPD)

    Time frame: 36 weeks postmenstrual age

    Infants were evaluated for oxygen need at 36 weeks postmenstrual age. If they required supplemental oxygen, they were diagnosed with BPD

  12. All Cause Mortality

    Time frame: admission to hospital discharge, up to 15 months

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Thrasher Research Fund

Registry information

Official study title

Dopamine Versus Vasopressin for Cardiovascular Support in Extremely Low Birth Weight Infants: A Randomized, Blinded Pilot Study

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Mar 18, 2011
Registry last updated
Feb 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.